List of Excipients in Branded Drug BENZACLIN

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Bausch Health US LLC	BENZACLIN	clindamycin phosphate and benzoyl peroxide	0187-5190	DOCUSATE SODIUM
Bausch Health US LLC	BENZACLIN	clindamycin phosphate and benzoyl peroxide	0187-5190	SODIUM HYDROXIDE
Bausch Health US LLC	BENZACLIN	clindamycin phosphate and benzoyl peroxide	0187-5190	WATER
Physicians Total Care Inc	BENZACLIN	clindamycin phosphate and benzoyl peroxide	54868-6062	SODIUM HYDROXIDE
Physicians Total Care Inc	BENZACLIN	clindamycin phosphate and benzoyl peroxide	54868-6062	WATER

BenzaClin Excipient Strategy and Commercial Opportunities

Last updated: August 9, 2026

BenzaClin is a mature fixed-dose topical acne product containing clindamycin phosphate 1.2% and benzoyl peroxide 5%. Its core composition is exposed to generic competition, so commercial value has shifted from the active ingredients to excipient-driven differentiation: chemical stability, skin tolerability, delivery format, packaging, shelf life, and patient adherence.

The most attractive opportunities are improved water activity control, low-irritation vehicles, airless packaging, preservative reduction, foam or pump delivery, and combination products that maintain clindamycin and benzoyl peroxide performance while reducing dryness and treatment discontinuation.

What is BenzaClin and how does its formulation work?

BenzaClin is a prescription topical gel for acne vulgaris. It combines an antibacterial lincosamide, clindamycin phosphate, with benzoyl peroxide, an oxidizing antimicrobial and keratolytic agent. The product is generally identified as clindamycin phosphate 1.2% and benzoyl peroxide 5% topical gel.[1]

The formulation has four technical requirements:

Formulation requirement	Role
Uniform suspension or dispersion	Keeps benzoyl peroxide evenly distributed through the gel
Controlled pH	Supports clindamycin phosphate stability and skin tolerability
Rheological control	Prevents settling while allowing easy spread and pump delivery
Packaging protection	Limits exposure to oxygen, light, heat and contamination

Benzoyl peroxide creates the principal formulation challenge. It can undergo decomposition under unfavorable temperature, moisture, light, metal-ion and pH conditions. Clindamycin phosphate presents a separate compatibility issue because the product must preserve an antibiotic in the presence of an oxidizing active ingredient.

What excipients are used in BenzaClin?

Public product labeling identifies a conventional aqueous gel system containing a carbomer polymer, dimethicone, glycerin, polysorbate 80, purified water and an alkaline neutralizer.[1] Exact inactive-ingredient descriptions can differ among branded and generic products.

Excipient class	Typical function in a BenzaClin-type product	Commercial relevance
Carbomer	Thickening, suspension and gel formation	Controls spreadability, sedimentation and pump performance
Dimethicone	Emolliency and skin-feel improvement	Can reduce the perception of dryness and improve cosmetic acceptability
Glycerin	Humectancy	Helps offset benzoyl peroxide-related dryness
Polysorbate 80	Wetting and dispersion support	Helps distribute hydrophobic benzoyl peroxide within the aqueous vehicle
Sodium or potassium hydroxide	Carbomer neutralization and pH adjustment	Influences viscosity, stability and irritation
Purified water	Continuous phase	Determines water activity, microbial risk and chemical stability

The excipients are not pharmacologically active, but they control the product's practical performance. A generic with the same active concentrations can still differ materially in viscosity, residue, drying time, irritation, odor, pumpability and patient acceptance.

Which excipient attributes are most important for BenzaClin?

Carbomer selection and neutralization

Carbomer grade is a major design variable. Molecular weight, crosslink density and polymer substitution affect viscosity, yield stress and shear-thinning behavior. A high-yield gel can keep benzoyl peroxide suspended, but excessive viscosity can impair dispensing and spreading.

Neutralization must be tightly controlled. Under-neutralized gels may be too thin and unstable. Over-neutralized systems may raise irritation risk or alter active-ingredient stability. The formulation target should be defined through viscosity, pH, particle-size distribution and redispersibility testing rather than by polymer concentration alone.

Humectant and emollient balance

Glycerin improves moisturization but can increase tack and drying time. Dimethicone can improve skin feel and reduce friction, although higher levels may affect optical appearance, residue and compatibility with packaging components.

A commercial reformulation could use a humectant blend or a silicone-compatible emollient system to reduce flaking without producing a greasy finish. The practical target is not maximum moisturization. It is improved tolerability while preserving rapid drying and low residue.

Surfactant minimization

Polysorbate 80 supports dispersion but can contribute to irritation or odor changes under certain storage conditions. A reformulator could evaluate lower surfactant levels, alternative nonionic wetting agents, polymeric dispersants or pre-dispersed benzoyl peroxide grades.

The regulatory burden increases if the replacement changes particle size, dispersion state, rheology or release. A safer development path is a controlled excipient substitution supported by comparative physical characterization and in vitro release testing.

pH control

pH affects carbomer viscosity, clindamycin phosphate stability, benzoyl peroxide decomposition and skin tolerability. A narrow pH specification is commercially valuable because batch-to-batch pH variation can translate into changes in texture and irritation.

Buffering should be used cautiously. A buffer can improve pH control but may introduce ionic-strength effects that lower carbomer viscosity or alter active-ingredient behavior. In many aqueous gels, low-buffer or unbuffered systems with controlled neutralization are preferable.

How can excipients improve BenzaClin stability?

The central stability strategy is to control water, oxygen, light, metals, temperature and interfacial contact.

Water activity and microenvironment control

BenzaClin-type gels are aqueous systems. Water supports clindamycin phosphate solubility and gel formation, but it also increases the potential for chemical degradation and microbial growth. Commercial development should evaluate:

• Reduced free-water environments
• Polyol combinations
• Hydroalcoholic or partially nonaqueous vehicles, where compatible
• Low-moisture packaging
• Preservative systems compatible with benzoyl peroxide

A fully anhydrous product is unlikely to be a direct BenzaClin substitute because clindamycin phosphate and the gel architecture depend on an appropriate aqueous environment. A more realistic opportunity is a lower-water or water-activity-controlled gel.

Chelation and metal control

Trace metals can catalyze peroxide decomposition. Chelating agents such as disodium EDTA may improve stability in some systems, but their use must be evaluated against pH, preservative performance, active-ingredient compatibility and regulatory requirements.

Raw-material specifications are as important as excipient selection. Carbomer, water, surfactants and packaging components should be controlled for trace metals and peroxide-reactive contaminants.

Antioxidant strategy

Conventional antioxidants may be unsuitable because benzoyl peroxide is itself an oxidizing active ingredient. Reducing agents can consume or destabilize benzoyl peroxide and should not be treated as routine stabilizers. The preferred strategy is often source control, packaging protection, chelation where justified, and control of thermal and photolytic exposure.

Packaging as a functional excipient system

Packaging is a major commercial differentiator. An airless pump can reduce oxygen ingress, contamination and repeated open-container exposure. It can also improve dose consistency and reduce product waste.

Potential packaging configurations include:

Format	Advantage	Main development issue
Airless pump	Better protection and clean dispensing	Compatibility, priming and residual volume
Metered-dose pump	Dose consistency	Device qualification and delivery uniformity
Tube	Low cost and familiar use	Repeated air exposure and contamination
Unit-dose sachet	Strong hygiene and portability	Higher packaging cost and waste
Dual-chamber system	Separates incompatible components until use	Greater device complexity and user burden
Foaming pump	Cosmetic appeal and rapid application	Active suspension, dose uniformity and foam stability

A dual-chamber system could be relevant if simultaneous storage of clindamycin and benzoyl peroxide materially limits shelf life. It would, however, require a clear adherence benefit to justify device complexity.

What formulation patents protect BenzaClin-type products?

The original fixed-combination concept is mature. The active-ingredient combination, basic aqueous gel architecture and principal clinical use have been available for many years, and the commercial market contains generic clindamycin phosphate and benzoyl peroxide topical products.

The strongest remaining intellectual-property opportunities are likely to be narrower formulation or device claims rather than broad claims covering clindamycin plus benzoyl peroxide. Potential claim categories include:

• Defined carbomer grades and concentration ranges
• Specific pH and viscosity windows
• Reduced-water or controlled-water-activity gels
• Improved benzoyl peroxide particle-size distributions
• Preservative-free or low-preservative systems
• Airless or metered packaging
• Defined release profiles
• Reduced-irritation excipient combinations
• Extended in-use stability
• Foams, sprays, films or microsuspensions
• Manufacturing processes that improve peroxide uniformity

Patent strength would depend on unexpected technical effects. A claim covering a routine substitution of one carbomer or humectant for another would face obviousness risk. Stronger protection would require comparative evidence showing a measurable improvement, such as longer peroxide stability, lower degradation products, improved delivery uniformity or clinically meaningful tolerability.

When does BenzaClin lose exclusivity?

BenzaClin's core market exclusivity is no longer the main commercial barrier. The product was approved more than two decades ago, and generic topical versions are available. A new entrant would generally pursue an abbreviated new drug application pathway if it could demonstrate pharmaceutical equivalence and bioequivalence or other applicable equivalence standards.[2]

Exclusivity category	BenzaClin position
New chemical entity exclusivity	Expired
Standard small-molecule product exclusivity	Expired
Core composition protection	Mature and commercially penetrated
Biosimilar exclusivity	Not applicable
Potential formulation exclusivity	Available only through new, defensible innovation
Device or packaging protection	Potentially available for differentiated delivery systems
Method-of-use protection	Limited value unless tied to a specific, non-obvious regimen

The product is not a biologic, so biosimilar risk is irrelevant. Competitive risk comes from ANDA applicants, authorized generics, branded generic manufacturers and differentiated topical formulations.

What is the FDA regulatory status and Orange Book position?

BenzaClin is an FDA-approved prescription topical combination product. Its regulatory pathway is a small-molecule drug pathway, not a biologic license application or biosimilar pathway.[1,2]

Orange Book value for the original product is limited by the age of the product and generic availability. Any remaining listed patents, if applicable to a specific product presentation, must be reviewed against the current FDA Orange Book rather than inferred from historical patent records.[3] Paragraph IV litigation is most relevant when a generic applicant challenges a still-listed patent. For a mature BenzaClin-type product, litigation risk is more likely to concern a newly patented reformulation, device or method of use than the original active-ingredient combination.

A reformulated product seeking three-year exclusivity based on a new clinical investigation would need to satisfy the statutory requirements for a new drug application supplement or new application. A new active-ingredient product is not created merely by changing excipients. Five-year new chemical entity exclusivity would not apply to a BenzaClin reformulation.

What commercial opportunities exist for BenzaClin excipient innovation?

1. Low-irritation acne gel

A vehicle that reduces burning, dryness, erythema and peeling could command value in dermatology practices and cash-pay channels. The most credible strategy combines humectancy, emolliency, optimized pH and controlled benzoyl peroxide dispersion.

Commercial proof should include tolerability endpoints, not only laboratory stability.

2. Premium airless pump

A stable, non-refrigerated or extended-use product in an airless pump could compete on convenience and reduced waste. Packaging protection is particularly valuable when benzoyl peroxide stability is sensitive to heat, light or repeated opening.

3. Preservative-reduced or preservative-free product

A preservative-reduced product could appeal to patients with sensitive skin. The formulation must still meet microbial limits throughout shelf life and in-use storage. Airless delivery can support the strategy but does not eliminate the need for microbiological validation.

4. Foam or fast-drying vehicle

A foam could improve spreadability and user acceptance over larger acne-prone areas. The technical risks include peroxide suspension, dose uniformity, propellant compatibility, container corrosion and stability of the foam structure.

5. Pediatric and adolescent adherence positioning

Adolescents are a commercially important population, but irritation and regimen complexity reduce persistence. A low-residue, rapidly drying gel with clear dose delivery could support adherence without changing the active ingredients.

6. Combination-platform expansion

The BenzaClin vehicle could support broader acne portfolios, including products containing adapalene, retinoids, azelaic acid or niacinamide. Each added active creates compatibility and regulatory complexity. The opportunity is strongest where the excipient platform solves a recognized problem, such as retinoid irritation or benzoyl peroxide instability.

How does BenzaClin compare with competing acne products?

Product type	Active strategy	Excipient opportunity
Benzoyl peroxide monotherapy	Antimicrobial and keratolytic	Lower irritation, better cosmetic feel
Clindamycin monotherapy	Antibiotic treatment	Resistance concerns and need for benzoyl peroxide pairing
Adapalene/benzoyl peroxide	Retinoid plus oxidizing antimicrobial	Stability, irritation control and layered delivery
Clindamycin/benzoyl peroxide	Antibiotic plus oxidizing antimicrobial	Vehicle tolerability, stability and adherence
Triple acne products	Multiple mechanisms	Compatibility, packaging and regimen simplification

BenzaClin's competitive weakness is not a lack of pharmacologic rationale. It is commoditization, topical irritation and the absence of a strong barrier to substitution. A differentiated excipient system must produce a visible patient or prescriber benefit.

What generic entry risks exist for BenzaClin?

Generic risk is high because:

1. The active ingredients and strengths are established.
2. The product is a conventional topical dosage form.
3. Patients and payers often accept substitution.
4. Formulation patents covering the original product are mature.
5. Multiple manufacturers can source standard excipients and packaging.

The principal barriers are technical equivalence, peroxide stability, active uniformity, rheology, microbial quality and container compatibility. These barriers can slow development but generally do not create durable exclusivity unless converted into valid formulation or device claims.

Key Takeaways

• BenzaClin contains clindamycin phosphate 1.2% and benzoyl peroxide 5% in a topical gel.
• The formulation's main technical risks are peroxide degradation, clindamycin compatibility, pH drift, viscosity variation and skin irritation.
• Carbomer, glycerin, dimethicone, polysorbate 80, water and alkaline neutralizers form the conventional excipient platform.
• The original active-ingredient combination is commercially mature and exposed to generic competition.
• The best new-product opportunities are low-irritation gels, airless pumps, preservative-reduced systems, foam delivery and improved in-use stability.
• A new patent position will require more than routine excipient substitution. Comparative stability, tolerability or delivery data will be central.
• BenzaClin is a small-molecule product. Biosimilar competition does not apply.
• Orange Book and Paragraph IV analysis should focus on any currently listed reformulation, device or method-of-use patents rather than the historical core combination.

FAQs

Can a new excipient create exclusivity for a BenzaClin generic?

Yes, but only if the formulation produces patentable technical distinctions and satisfies FDA requirements for the selected regulatory pathway. A routine excipient replacement is unlikely to provide durable protection by itself.

Is benzoyl peroxide compatible with carbomer gels?

Yes. Carbomer is widely used in benzoyl peroxide topical systems, but grade, neutralization, pH, peroxide particle size and trace-metal control must be optimized together.

Would an airless pump improve BenzaClin shelf life?

It can reduce contamination and exposure to air and environmental conditions. The benefit must be demonstrated through stability, delivery-uniformity and container-closure studies.

Can BenzaClin be converted to an over-the-counter product?

Benzoyl peroxide is widely used in over-the-counter acne products, but clindamycin is a prescription antibiotic. A fixed combination containing clindamycin would require a separate FDA regulatory strategy and would not automatically qualify for OTC status.

What is the most defensible commercial reformulation strategy?

A low-irritation, rapidly drying, airless-pump gel with demonstrated peroxide stability and improved patient tolerability offers the strongest balance of technical feasibility, clinical value and patent potential.

References

1. U.S. Food and Drug Administration. (n.d.). BenzaClin: Clindamycin phosphate and benzoyl peroxide topical gel prescribing information. DailyMed.

2. U.S. Food and Drug Administration. (2016). Product-specific guidance for clindamycin phosphate; benzoyl peroxide topical gel. FDA.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Center for Drug Evaluation and Research.